Loading...

TBPH THERAVANCE BIOPHARMA INC Product Launches 8-K Filing

THRV

TBPH

THERAVANCE BIOPHARMA INC

(TBPH)

2025 8-K

Settlement Agreement

Financial Results Update

Financial Restructuring

Investor Meetings Scheduled

Investor Event Announced

Financial Update

Enrollment Complete

Settlement Agreement

Contract Renewal

Asset Acquisitions

Financial Statements

Financial Results

Q3 Earnings Report

Patent Settlement

Investor Conference

Annual General Meeting

Settlement Agreement for YU...

Settlement Agreement for YU...

Cooperation Agreement

Settlement Agreement for YU...

Investor Conferences

Termination of License Agre...

Changes to Equity Incentive...

Presentation at Needham Vir...

Appointment of James C. Kel...

Business Update and Investo...

External Links:

On August 25, 2025, Theravance Biopharma, Inc. announced the completion of enrollment in its Phase 3 CYPRESS study for treating neurogenic orthostatic hypotension due to multiple system atrophy. This is a significant event for the company.

AI Assistant

THERAVANCE BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.